"This Phase Ib/IIa study is a multicenter open label trial of the combination of IPH2201 and ibrutinib in patients with relapsed or refractory Chronic Lymphocytic Leukemia. Its primary objective is to evaluate the anti-leukemic activity of the combination and the primary endpoint for efficacy is complete response rate. The secondary objectives are to assess the safety of the combination of IPH2201 and ibrutinib. The trial will be performed in the United States under the coordination of leading investigators at the Ohio State University.
Quite different Jeff and beyond my current understanding. As I understand it, the IPH2201 isn't actually targeting the CLL cells but a checkpoint inhibitor in T and Natural Killer Lymphocytes. The reasoning behind the trial design is that CLL cells express greater quantities of a protein (HLA-E) on their cell membrane which stops our T and Natural Killer (NK) Lymphocytes from recognising them as cancerous cells and killing them. The IPH2201 binds to the NGK2A checkpoint inhibitor in T and NK cells, blocking that inhibition by the CLL cells. That enables the T and NK cells to work in concert with the Ibrutinib to wipe out the CLL cells.
Thank you for posting. It is exciting to see the new developments arise. For those of us with CLL it is hope that as the effectiveness of one treatment runs out there can be another to follow.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
